详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Hepatoid Adenocarcinoma of the Stomach Combined With Gastric Neuroendocrine Carcinoma: A Case Report

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [2]Department of Pathology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China [3]Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China

出处：

DOI：

ISSN：

关键词： case report gastric neuroendocrine carcinoma hepatoid adenocarcinoma of the stomach immunotherapy liver metastasis targeted therapy

摘要：

Both hepatoid adenocarcinoma of the stomach (HAS) and gastric neuroendocrine carcinoma (NEC) are rare subtypes of gastric cancer, characterized by aggressive behavior and poor prognosis, for which no definitive treatment regimen has been established to date. A 56-year-old male was diagnosed with HAS combined with NEC, accompanied by perigastric lymph node and liver metastases. Initially, he received EP chemotherapy, which was subsequently switched to a regimen of capecitabine plus oxaliplatin due to insufficient therapeutic response. Ultimately, the treatment was transitioned to a combination of immunotherapy and targeted therapy with Lenvatinib plus Envafolimab, owing to the development of capecitabine intolerance. The optimal management of this disease remains undefined, and conventional chemotherapy often results in suboptimal outcomes. However, in this case, the treatment with Lenvatinib plus Envafolimab appears to be an effective strategy for prolonging survival time and improving quality of life. Further experimental and clinical investigations are warranted to validate these findings and substantiate this therapeutic hypothesis.© 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 4 区医学

小类 | 4 区医学：内科

最新[2025]版：

大类 | 4 区医学

小类 | 4 区医学：内科

第一作者：

第一作者机构： [1]Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report [2]The preliminary outcome of the combination of immunotherapy and targeted therapy after recurrence and metastasis for hereditary leiomyomatosis and renal cell cancer-a case report. [3]Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer [4]Remarkable response to Osimertinib plus Gumarontinib for EGFR mutation and concomitant MET exon 14 skipping in a patient with lung adenocarcinoma: A case report [5]Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study [6]Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review [7]Clinical characteristics from a case of primary neuroendocrine carcinoma in the renal pelvis [8]Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment [9]Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study [10]En bloc resection of the recurrent pleural mesothelioma and reconstruction of the chest wall after immunotherapy: A case report